Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$669 Mln
P/E Ratio
--
P/B Ratio
1.44
Industry P/E
--
Debt to Equity
0.02
ROE
-1.06 %
ROCE
-105 %
Div. Yield
0 %
Book Value
1.38
EPS
-1.69
CFO
$-269.47 Mln
EBITDA
$-369.28 Mln
Net Profit
$-283.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nuvation Bio Inc. Class A (NUVB)
| -24.81 | 5.82 | -22.48 | -23.08 | -28.62 | -- | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Nuvation Bio Inc. Class A (NUVB)
| 75.35 | -21.35 | -77.41 | -27.35 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.21 | 9,973.38 | 20.56 | 23.13 | |
| 275.30 | 8,956.07 | 23.48 | 58.42 | |
| 25.41 | 9,559.25 | -- | -28.77 | |
| 101.29 | 10,030.35 | 30.81 | 14.16 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for... the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York. Address: 1500 Broadway, New York, NY, United States, 10036 Read more
Founder, President, CEO & Director
Dr. David T. Hung M.D.
Chief Scientific Officer
Dr. Gary Hattersley Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nuvation Bio Inc Class A (NUVB) stood at $ 541 Mln as on 31-Dec-24
The share price of Nuvation Bio Inc Class A (NUVB) is $2.00 (NYSE) as of 22-Apr-2025 13:34 EDT. Nuvation Bio Inc Class A (NUVB) has given a return of -28.62% in the last 3 years.
Nuvation Bio Inc Class A (NUVB) has a market capitalisation of $ 669 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Nuvation Bio Inc Class A (NUVB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nuvation Bio Inc Class A (NUVB) and enter the required number of quantities and click on buy to purchase the shares of Nuvation Bio Inc Class A (NUVB).
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York. Address: 1500 Broadway, New York, NY, United States, 10036
The CEO & director of Dr. David T. Hung M.D.. is Nuvation Bio Inc Class A (NUVB), and CFO & Sr. VP is Dr. Gary Hattersley Ph.D..
There is no promoter pledging in Nuvation Bio Inc Class A (NUVB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Nuvation Bio Inc. Class A (NUVB) | Ratios |
|---|---|
|
Return on equity(%)
|
-106.27
|
|
Operating margin(%)
|
-7209.42
|
|
Net Margin(%)
|
-7213.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nuvation Bio Inc Class A (NUVB) was $0 Mln.
$0.02
(
